Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amg-548. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 2/20 | 1.00 |
| ▸ | PRKCI | P41743 | 14/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 3/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 1/20 | 1.00 |
| ▸ | CAMK2B | Q13554 | 1/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amg-548 SCHEMBL433426 | 1.00 | PRKCI (1.00) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| Amg-548 SCHEMBL29395852 | 1.00 | PRKCI (1.00) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| Amg-548 SCHEMBL433425 | 1.00 | PRKCI (1.00) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934599 | 0.89 | PRKCI (0.81) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934604 | 0.89 | PRKCI (0.81) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934602 | 0.89 | PRKCI (0.81) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934628 | 0.89 | MAPK9 (0.82) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934623 | 0.89 | MAPK9 (0.82) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL6934627 | 0.89 | MAPK9 (0.82) | PRKCIMAPK9MAPK13MAPK14MAP4K4 | |
| SCHEMBL4820989 | 0.89 | MAPK9 (0.80) | PRKCIMAPK9MAPK13MAPK14MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | claimed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | claimed |
| US-20250302883-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | disclosed |
| US-20230057984-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20220226318-A1 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2022-07-21 | — | — | US | disclosed |
| US-20220226340-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2022-07-21 | — | — | US | disclosed |
| CN-114650818-A | Casein kinase 1 inhibitors for the treatment of diseases associated with DUX4 expression such as muscular dystrophy and cancer | FACIO知识产权有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3982955-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2022-04-20 | — | — | EP | disclosed |
| US-20210177847-A1 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2021-06-17 | — | — | US | disclosed |
| EP-3381472-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF- SIGNALS, AND APPLICATION THEREOF | The Doshisha (JP) | 2018-10-03 | — | — | EP | disclosed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | disclosed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | disclosed |
| US-20150044178-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| US-8906953-B2 | Pyrrolidine substitute flavones for the treatment of inflammatory disorders | Piramal Enterprises Limited (IN) | 2014-12-09 | — | — | US | disclosed |
| EP-2538941-A1 | PYRROLIDINE SUBSTITUTED FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316216-A1 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2012-12-13 | — | — | US | disclosed |
| WO-2011104584-A1 | PYRROLIDINE SUBSTITUTED FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-09-01 | — | — | WO | disclosed |
| US-20080119498-A1 | Therapeutic Agent for Pruritus Comprising P38 Map Kinase Inhibitor as the Active Ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177847-A1 | Compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | MAPK14 4269/4885PRKCI 2319/4885MAPK9 4182/4885 |
| US-20120316216-A1 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, SYVN1, PAH | MAPK14 1122/4885PRKCI 3963/4885MAPK9 3028/4885 |
| US-20220226340-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | CSNK1A1, CSNK1G3, CSNK1G1 | MAPK14 818/4885PRKCI 115/4885MAPK9 774/4885 |
| US-20220226318-A1 | Compounds for treatment of diseases related to DUX4 expression | ZFX, MTPN, UTRN | MAPK14 4441/4885PRKCI 2000/4885MAPK9 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.